The Patent Finder

Stoke Therapeutics, Inc.

10 patents currently held · Updated Nov 17, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Dec 2036
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due May 14, 2027
    The maintenance fee for OPA1 Antisense Oligomers for Treatment of Conditions and Diseases (US 11,814,622) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.
  • 1 fee due Jul 16, 2027
    The maintenance fee for Antisense Oligomers for Treatment of Conditions and Diseases (US 11,873,490) comes due Jul 16, 2027. Unpaid by Jan 18, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 2 of the patents on this record were granted since Aug 19, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 10 of 10

PatentTitleStatus Expires Confidence
US 11,083,745Antisense oligomers for treatment of autosomal dominant mental retardation-5 and Dravet Syndrome
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,683,503Antisense Oligomers for Treatment of Conditions and Diseases
In force
 · Medium confidence
In forceMedium confidence
US 10,913,947Antisense Oligomers for Treatment of Conditions and Diseases
In force
 · Low confidence
In forceLow confidence
US 11,873,490Antisense Oligomers for Treatment of Conditions and Diseases
In force
 · Low confidence
In forceLow confidence
US 12,577,561Antisense Oligomers for Treatment of Conditions and Diseases
In force
 · Medium confidence
In forceMedium confidence
US 12,797,487Antisense Oligomers for Treatment of Non-Sense Mediated RNA Decay Based Conditions and Diseases
In force
 · High confidence
In forceHigh confidence
US 11,814,622OPA1 Antisense Oligomers for Treatment of Conditions and Diseases
In force
 · High confidence
In forceHigh confidence
US 12,753,408OPA1 Antisense Oligomers for Treatment of Conditions and Diseases
In force
 · High confidence
In forceHigh confidence
US 12,338,437OPA1 Antisense Oligomers for Treatment of Conditions and Diseases
In force
 · High confidence
In forceHigh confidence
US 12,060,558Methods and compositions for treatment of cholesteryl ester storage disease
In force
 · From the USPTO record
In forceFrom the USPTO record
Also on record, not counted in the 10: 1 patent in force now held by others. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

12 pending · 1 abandoned · 2 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited